MYC Amplification as a Prognostic Marker of Early-Stage Lung Adenocarcinoma Identified by Whole Genome Copy Number Analysis
MYC Amplification as a Prognostic Marker of Early-Stage Lung Adenocarcinoma Identified by Whole Genome Copy Number Analysis
复制标题
DOI：
10.1158/1078-0432.ccr-10-2484
复制
发表时间：
2011-03-15
影响因子：
11.5
通讯作者：
Yokota, Jun
中科院分区：
文献类型：
--
作者：
Iwakawa, Reika;Kohno, Takashi;Yokota, Jun
目的：即使在小型(10%)ADC和肺ADC细胞系中扩增。MYC基因定位于染色体8q24.21的最小共同区域，是肺ADC基因扩增的靶点。MYC扩增与小ADC患者预后不良相关(P=0.031)。SNP芯片分析检测到的MYC扩增与RT-G-PCR分析重复性较好。因此，为了探讨MYC扩增作为早期肺ADC预后标志物的价值，对162例I期肺ADC进行了分析。在这些患者中，MYC基因扩增与无复发生存率相关(多因素COX比例风险模型分析，P=0.013)。结论：这些结果强烈表明MYC基因扩增是早期肺ADC患者的预后标志。临床癌症资源；17(6)；1481-9。(C)2010年AACR。
Purpose: Even in small-sized (10%) amplified in both small-sized ADCs and lung ADC cell lines. In particular, the MYC gene was mapped in the minimum common region at chromosome 8q24.21, and therefore was indicated to be a target of gene amplification in lung ADCs. MYC amplification correlated with poor prognosis (P = 0.031) of patients with small-sized ADCs. MYC amplification detected by SNP array analysis was well reproduced by RT-G-PCR analysis. Therefore, to investigate the utility of MYC amplification as a prognostic marker for early-stage lung ADCs, 162 stage I lung ADCs were subjected to the analysis. MYC amplification was associated with relapse-free survival in these patients (P = 0.013 by multivariate Cox proportional hazard model analysis).Conclusions: These results strongly indicate that MYC amplification is a prognostic marker of patients with early-stage lung ADCs. Clin Cancer Res; 17(6); 1481-9. (C) 2010 AACR.